Latest Insider Transactions at Liquidia Corp (LQDA)
This section provides a real-time view of insider transactions for Liquidia Corp (LQDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Liquidia Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Liquidia Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
Dana Boyle Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+11.72%
|
-
|
|
Jul 01
2025
|
Sarah Krepp Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+14.69%
|
-
|
|
Jun 17
2025
|
Stephen M Bloch Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
Damian De Goa Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+17.54%
|
-
|
|
Jun 17
2025
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
Arthur S Kirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+31.1%
|
-
|
|
Jun 17
2025
|
Paul B Manning Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
Katherine Rielly Gauvin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
Raman Singh Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
David Edward Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 04
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,597
-2.71%
|
$121,552
$16.97 P/Share
|
|
Jun 04
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,656
-2.87%
|
$106,496
$16.97 P/Share
|
|
Jun 04
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
8,460
-1.43%
|
$135,360
$16.97 P/Share
|
|
Jun 04
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,597
-1.82%
|
$57,552
$16.97 P/Share
|
|
Jun 04
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
14,777
-3.46%
|
$236,432
$16.97 P/Share
|
|
Jun 04
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,610
-2.85%
|
$489,760
$16.97 P/Share
|
|
Jun 03
2025
|
Rajeev Saggar Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,654
+5.92%
|
-
|
|
Jun 03
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,539
+6.29%
|
-
|
|
Jun 03
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
18,792
+3.08%
|
-
|
|
Jun 03
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,371
+5.9%
|
-
|
|
Jun 03
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,141
+6.39%
|
-
|
|
Jun 03
2025
|
Roger Jeffs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,169
+6.04%
|
-
|
|
Jun 02
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
859
-0.22%
|
$13,744
$16.74 P/Share
|
|
Jun 02
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
581
-0.27%
|
$9,296
$16.74 P/Share
|
|
Jun 02
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
923
-0.16%
|
$14,768
$16.74 P/Share
|
|
Jun 02
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
451
-0.24%
|
$7,216
$16.74 P/Share
|
|
May 30
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.58%
|
-
|
|
May 30
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+0.86%
|
-
|
|
May 30
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.41%
|
-
|
|
May 30
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+0.84%
|
-
|
|
Apr 28
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.25%
|
$6,370
$14.24 P/Share
|
|
Apr 21
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,450
-0.92%
|
$31,850
$13.67 P/Share
|
|
Apr 15
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,406
-1.56%
|
$44,278
$13.57 P/Share
|
|
Apr 14
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,130
-1.38%
|
$183,690
$13.57 P/Share
|
|
Apr 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
5,964
-1.03%
|
$77,532
$13.57 P/Share
|
|
Apr 14
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,714
-1.38%
|
$48,282
$13.57 P/Share
|
|
Apr 14
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
8,283
-2.05%
|
$107,679
$13.57 P/Share
|
|
Apr 14
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,856
-1.0%
|
$24,128
$13.57 P/Share
|
|
Apr 11
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+2.06%
|
-
|
|
Mar 03
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
451
-0.25%
|
$6,765
$15.45 P/Share
|
|
Mar 03
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
874
-0.22%
|
$13,110
$15.45 P/Share
|
|
Mar 03
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
592
-0.27%
|
$8,880
$15.45 P/Share
|
|
Mar 03
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
930
-0.16%
|
$13,950
$15.45 P/Share
|
|
Feb 28
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+0.85%
|
-
|
|
Feb 28
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.57%
|
-
|
|
Feb 28
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+0.85%
|
-
|
|
Feb 28
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.4%
|
-
|
|
Jan 27
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
445
-0.25%
|
$6,230
$14.2 P/Share
|
|
Jan 21
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,445
-0.9%
|
$31,785
$13.0 P/Share
|
|
Jan 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
16,393
-2.78%
|
$180,323
$11.78 P/Share
|